Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read-along companion piece! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150 Landing Page: https://ebrheum.com/ Substack: https://autoimmunedevreport.substack.com/
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Evidence Based Rheumatology Podcast
E135: IL17 and a GLP1?
E134: Brepocitinib in Dermatomyositis (VALOR)
E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
E131: A Sham-Controlled Sham of a Trial: RESET-RA
Get summaries like this every morning.
Free AI-powered recaps of The Evidence Based Rheumatology Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.